GLP-1 receptor agonists are not associated with increased diabetic macular edema risk in real-world dataComparing Eye Health Risks Between Different Types of Diabetes Medications

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie Published October 4, 2026 Study authors: Al-Burak Salem Abu, Voznyy Vitaliy, Elganga Mouad, Zajner Chris, Juncal Verena, Sheidow Thomas G, Ma… PubMed ↗ DOI ↗ Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that GLP-1RAs are not associated with increased diabetic macular edema risk in this low-certainty observational meta-analysis.

This meta-analysis synthesized real-world database evidence to evaluate the incidence of diabetic macular edema (DME) in patients with type 2 diabetes treated with GLP-1 receptor agonists (GLP-1RAs). The analysis compared GLP-1RAs against mixed antihyperglycemic therapies, SGLT2 inhibitors, and DPP-4 inhibitors.

The pooled proportion of incident DME in GLP-1RA users was 0.14 (95% CI: 0.07-0.23). When compared specifically to mixed antihyperglycemic therapies, GLP-1RAs were not associated with increased DME risk (0.81; 95% CI: 0.52-1.26). Similarly, GLP-1RAs were not associated with increased risk when compared to DPP-4 inhibitors (0.90; 95% CI: 0.69-1.19). In contrast, GLP-1RAs showed a higher relative risk of DME when compared to SGLT2 inhibitors (1.50; 95% CI: 1.17-1.94).

The authors note that the evidence is of very low certainty because the data are derived from observational studies. Clinical practice relevance is limited by these findings; while current data do not support an overall increased risk of DME with GLP-1RA use, the results are based on observational data and should be interpreted with caution.

How this fits prior evidence

This meta-analysis addresses a gap regarding the safety of GLP-1 receptor agonists in patients with type 2 diabetes. While previous coverage noted that SGLT2 inhibitors improve glycemic control and blood pressure in patients with diabetic chronic kidney disease, this meta-analysis provides specific data on the risk of diabetic macular edema. The findings suggest that GLP-1RAs do not increase DME risk compared to mixed therapies or DPP-4 inhibitors, though a higher relative risk was noted specifically when compared to SGLT2 inhibitors.

Doctors are looking closely at how different medications affect the eyes of people living with Type 2 Diabetes. One specific concern is a condition called diabetic macular edema, which can cause vision problems. This study looked at patients who were not originally diagnosed with this eye condition to see if certain drugs caused it over time.

The study compared GLP-1 receptor agonists to other common treatments like SGLT2 inhibitors and DPP-4 inhibitors. The results showed that patients taking GLP-1 medications did not have a higher risk of developing eye issues compared to those on mixed therapies or DPP-4 inhibitors.

However, the data did show a higher chance of eye issues for those taking GLP-1 medications when compared specifically to SGLT2 inhibitors. Because this information comes from real-world records rather than a controlled trial, the certainty of these findings is currently low. Doctors can use this to help weigh the benefits and risks of different treatment plans.

What this means for you:

GLP-1 medications do not show a higher risk of eye issues compared to most other common diabetes treatments.

Common questions

Do GLP-1 medications cause eye swelling in people with diabetes?

The study found that GLP-1 receptor agonists were not associated with an increased risk of diabetic macular edema (eye swelling) when compared to mixed therapies or DPP-4 inhibitors. However, the evidence is of low certainty because it comes from observational data rather than a controlled trial.

How do GLP-1 medications compare to SGLT2 inhibitors for eye health?

When comparing the two specifically, the study found a higher relative risk of eye swelling for those taking GLP-1 receptor agonists compared to those taking SGLT2 inhibitors. You should talk to your doctor about which medication is best for your specific needs.

Is the evidence for these findings reliable?

The researchers noted that the evidence is of low certainty. Because the data comes from real-world databases rather than a strictly controlled clinical trial, the findings show an association but do not prove a direct cause.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedOct 2026

PMID42242293

View Original Abstract ↓

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type II diabetes and obesity because of their cardiometabolic benefits. However, concerns regarding potential ocular adverse effects, particularly diabetic macular edema (DME), have prompted the need to clarify their retinal safety. METHODS: A systematic review and meta-analysis study was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-analysis of Observational Studies in Epidemiology statements (PROSPERO registration: CRD420251176164). MEDLINE (Ovid), EMBASE (Ovid), CENTRAL (Ovid), Web of Science, and PubMed were searched from inception to October 24, 2025. Randomized trials and observational cohort or case-control studies, including individuals with diabetes without baseline DME and exposed to GLP-1RAs were eligible. Two reviewers independently screened studies, extracted data, and assessed risk of bias using ROBINS-I. Certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development, and Evaluation. Random-effects models were used to pool incidence proportions and hazard ratios (HRs). RESULTS: Thirteen retrospective cohort studies (2021-2025) using large real-world databases were included. Across 6 studies, the pooled proportion of incident DME among GLP-1RA users was 0.14 (95% CI: 0.07-0.23; I² = 99.8%). Compared with mixed antihyperglycemic therapies, GLP-1RA use was not associated with increased DME risk (pooled HR: 0.81, 95% CI: 0.52-1.26). GLP-1RAs were associated with a higher relative risk of DME compared with sodium-glucose cotransporter-2 inhibitors (HR: 1.50, 95% CI: 1.17-1.94) but not compared with dipeptidyl peptidase-4 inhibitors (HR: 0.90, 95% CI: 0.69-1.19). Evidence certainty was very low. CONCLUSION: Current low-certainty observational evidence does not support an overall increased risk of DME with GLP-1RA use. Prospective studies are needed to clarify comparative retinal safety.

GLP-1 receptor agonists are not associated with increased diabetic macular edema risk in real-world dataComparing Eye Health Risks Between Different Types of Diabetes Medications

How this fits prior evidence

Common questions

Study Details

SGLT2 inhibitors reduce risk of diabetic retinopathy progression (rr 0.77) and macular edema progression (rr 0.75)

SGLT2 inhibitors show promise in slowing diabetic eye disease

Clinical research that matters. Delivered to your inbox.

GLP-1 receptor agonists are not associated with increased diabetic macular edema risk in real-world dataComparing Eye Health Risks Between Different Types of Diabetes Medications

How this fits prior evidence

Common questions

More on Type 2 Diabetes

Study Details

SGLT2 inhibitors reduce risk of diabetic retinopathy progression (rr 0.77) and macular edema progression (rr 0.75)

SGLT2 inhibitors show promise in slowing diabetic eye disease

Clinical research that matters. Delivered to your inbox.

Related in Ophthalmology

From Other Specialties